Planet 13 Flips the Schedule: Rescheduling Rewrites the Cannabis P&L

Federal Schedule III and hemp crackdowns target the company's two biggest structural headwinds — 280E taxes and illicit competition — just as the transition drag clears.

PLNH · Earnings Call · 2026-05-13

The Schedule III Inflection

Planet 13's Q1 2026 call was less about the numbers and more about the ground shifting beneath the industry. Bob Groesbeck called it “the most consequential thing that has happened in the industry in the past 5 years” — Robert Groesbeck, Chief Executive Officer · 2026-05-13 — the signing of the final order moving medical marijuana from Schedule I to Schedule III. The company's Florida operations, roughly 40% of revenue, are directly in scope. The immediate effect is the end of 280E for that business, which Steve McLean described as “fundamentally changing the federal tax treatment of our Florida business” — Steve McLean, Chief Financial Officer · 2026-05-13. This is not a niche catalyst; it removes a punitive tax regime that has suppressed margins for every licit operator.

The most important consequence, as Steve described, is that 280E, the federal tax provision that has imposed a punitive effect rate on license operators for decades, no longer applies to our Florida business on a go-forward basis.
Robert Groesbeck, Chief Executive Officer · 2026-05-13

The keyword trajectory confirms this is fresh, not boilerplate: Medical Marijuana license and Schedule III both spiked to the top of the company's recent quarter keywords with momentum scores well above any prior themes. For a company that has been fighting a persistent drag from taxes and a macro slump, this is a genuine strategic pivot.

From Transition to Turnaround

Q1 was framed as the cost of repositioning: the California exit ($2.5M of quarterly revenue removed), the Wagon Trail consolidation, and a one-time Florida loyalty accrual that did not repeat. Underlying retail was roughly flat sequentially, but the real signal was April. Larry Scheffler noted “Q1 was a transition quarter that reflected the cost of the strategic repositioning we've executed over the past several quarters... with the benefit beginning to show up in our April results.” — Larry Scheffler, Chief Operating Officer · 2026-05-13 Gross margin held at 44.6% (up 5.4% excluding the loyalty item), and the company expects to see gross margin reach the low-50s as the BHO lab ramps and the California inventory drag is gone. Prior calls had laid the groundwork: Steve McLean had guided earlier that “we're expecting to see margins north of 50% starting in the first quarter” — Steve McLean, Chief Financial Officer · 2026-03-25 — that hasn't quite materialized, but management is emphatic that the heavy lifting is done. Florida operation is the center of gravity. The BHO lab — awaiting final approval — is expected to plug a major product gap and boost comparable sales in the back half. The company is deliberately holding Florida store count at 30 to preserve cash, with Larry telling analysts “we're just holding tight on our stores in Florida right now until we see if and what is going to happen... while cash is king” — Larry Scheffler, Chief Operating Officer · 2026-05-13.

Hemp Set to Retreat

The second structural headwind is intoxicating hemp proliferation, particularly in Las Vegas. A Clark County ordinance takes effect mid-July, and the federal Farm Bill restrictions follow in November. On the Q&A call, Bob was candid: “we do expect as we get closer to that July time frame, we're going to see some significant uptick in improvements on our end as those stores start to close.” — Robert Groesbeck, Chief Executive Officer · 2026-05-13 This is a direct revenue recovery catalyst for the SuperStore, which has seen foot traffic diverted. The combination — rescheduling ending 280E and hemp enforcement clawing back illicit competition — attacks the two largest drains on profitability. The company has already seen California exit improve the mix, and the balance sheet is stabilizing: effective net cash turned from $61M in 2021 to a -$15M position, but cash burn has slowed sharply. The stock has been a disaster — down over 98% from its 2021 peak — but it's up 7.4% in the last 90 days with a 31% bounce in the last 9 sessions, suggesting the market is starting to price in the turnaround. This is a classic deep-value situation with a specific catalyst: the regulatory flip is company-specific but aligns with broader political tailwinds. The key execution risk is whether the BHO approval and the hemp clampdown actually translate to margin and revenue inflection by Q3. Management says the operating model is now where they want it; the numbers will speak soon.